Clinical Trial Update: Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements [Phase 3]

View source ↗

Summary

Phase 3 trial comparing futibatinib to gemcitabine-cisplatin as first-line treatment for advanced cholangiocarcinoma with FGFR2 gene rearrangements; the study w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Futibatinib (futibatinib)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements | Phase 3 | Status: TERMINATED | Results posted: 2025-02-07